AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.260

+0.0051.96%

Volume:376.18K

Turnover:96.89K

Market Cap:114.21M

PE:-4.36

High:0.260

Open:0.255

Low:0.255

Close:0.255

52wk High:0.500

52wk Low:0.255

Shares:439.25M

Float Shares:353.07M

Volume Ratio:3.14

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.060

EPS(LYR):-0.060

ROE:-180.22%

ROA:-82.94%

PB:19.04

PE(LYR):-4.36

Loading ...

Overview Company News Filings

BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$23.2 Million

Paradigm Biopharmaceuticals Ltd - Hy Revenue From Continuing Activities a$284,055

THOMSON REUTERS

Paradigm Says Study Evaluating Lead Product in Canine Arthritis Show Sustained Reductions in Chronic Pain

MT Newswires Live

BRIEF-Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply Agreement

Paradigm Biopharmaceuticals Secures Binding Term Sheet With Veterinary Pharmaceutical Company; Shares Up 3%

MT Newswires Live

Paradigm Biopharmaceuticals Ltd - Signs Binding Veterinary Licensing & Supply Agreement for Oral PPS + Cox-2 Inhibitor Combination

THOMSON REUTERS

Paradigm Biopharmaceuticals -Co Eligible to Receive up to a$1 Mln From Avet in Development Milestones

THOMSON REUTERS

Paradigm Biopharmaceuticals Ltd-Change of Director's Interest Notice

THOMSON REUTERS

Papa John's International Collaborates With PAR Technology to Modernize Restaurant Operations

MT Newswires Live

Paradigm Biopharmaceuticals Moves to Reach Patient Recruitment Milestone in Phase 3 Knee Osteoarthritis Trial

MT Newswires Live

PAR Technology (PAR) Valuation After Wasatch Exit and Ongoing Cash Burn Concerns

Simply Wall St.

PAR Technology (PAR) Taps Wallet-Based Loyalty But How Durable Is Its Restaurant Software Edge?

Simply Wall St.

Paradigm Biopharmaceuticals Withdraws About $5 Million From Convertible Note Facility; Shares Rise 7%

MT Newswires Live

PAR Technology Launches Catering Platform to Help Chains Manage Large Orders

MT Newswires Live

Paradigm Biopharmaceuticals Engages Complementary Contract Research Organization to Support Knee Osteoarthritis Trial; Shares Fall 5%

MT Newswires Live

PAR Technology (PAR) Is Up 9.4% After AI Platform Launch and 23% Revenue Growth in Q3

Simply Wall St.

Paradigm Biopharmaceuticals Enters Phase Three Trial Dosing Phase for Knee Osteoarthritis Pain in the September Quarter

MT Newswires Live

Can Paradigm Biopharmaceuticals' (ASX:PAR) Leadership Vision Drive Long-Term Strategic Value?

Simply Wall St.

Paradigm Biopharmaceuticals (ASX:PAR): Assessing Valuation as Investor Focus Builds Ahead of Ignite Summit Presentation

Simply Wall St.

Paradigm Biopharmaceuticals (ASX:PAR) Raises Capital—Will New Funds Accelerate Its Therapeutic Pipeline?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PAR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.26,"timestamp":1772494579933,"preClose":0.255,"halted":0,"volume":376179,"delay":0,"changeRate":0.01960784313725492,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":439254435,"eps":-0.059699,"marketStatus":"Trading","change":0.005,"latestTime":"03-03 10:36:27 AEDT","open":0.255,"high":0.26,"low":0.255,"amount":96888,"amplitude":0.019608,"askPrice":0.26,"askSize":171411,"bidPrice":0.255,"bidSize":607062,"shortable":3,"etf":0,"ttmEps":-0.059699,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772514000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.255,"openAndCloseTimeList":[[1772492400000,1772514000000]],"volumeRatio":3.144011,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-82.94%","roe":"-180.22%","lyrEps":-0.059684,"volumeRatio":3.144011,"shares":439254435,"dividePrice":0,"high":0.26,"amplitude":0.019608,"preClose":0.255,"low":0.255,"week52Low":0.255,"pbRate":"19.04","psRate":"13515.52","week52High":0.5,"institutionHeld":0,"latestPrice":0.26,"committee":0.559622,"eps":-0.059699,"divideRate":0,"volume":376179,"delay":0,"ttmEps":-0.059699,"open":0.255,"prevYearClose":0.34,"prevWeekClose":0.26,"prevMonthClose":0.26,"prevQuarterClose":0.34,"fiveDayClose":0.27,"twentyDayClose":0.315,"sixtyDayClose":0.35,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614967009","title":"BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$23.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614967009","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614967009?lang=en_us&edition=fundamental","pubTime":"2026-02-27 09:48","pubTimestamp":1772156885,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$23.2 MillionFeb 27 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:HY NET LOSS ATTRIBUTABLE A$23.2 MILLIONHY  REVENUE FROM CONTINUING ACTIVITIES A$284,055Further company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM26V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PAR.AU","BK7508"],"gpt_icon":0},{"id":"2614764530","title":"Paradigm Biopharmaceuticals Ltd - Hy  Revenue From Continuing Activities a$284,055","url":"https://stock-news.laohu8.com/highlight/detail?id=2614764530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614764530?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:13","pubTimestamp":1772140383,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM26V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PAR.AU","BK7067"],"gpt_icon":0},{"id":"2610187608","title":"Paradigm Says Study Evaluating Lead Product in Canine Arthritis Show Sustained  Reductions in Chronic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2610187608","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610187608?lang=en_us&edition=fundamental","pubTime":"2026-02-11 08:30","pubTimestamp":1770769806,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said a study of its lead product, pentosan polysulfate sodium , in canine osteoarthritis showed sustained reductions in chronic pain and normalization of gait symmetry through 26 weeks, compared with placebo, according to a Wednesday filing with the Australian bourse.The study assesses the durability and potential disease-modifying effects of a six-week course of PPS in dogs with naturally occurring osteoarthritis of the stifle and/or elbow joints, the filing said.Following the treatment, magnetic resonance imaging and serum biomarker findings were consistent with slowed cartilage degradation and altered bone and cartilage turnover, the filing said.The study also provides a compressed analogue of longer-term human outcomes, the filing added.Shares of the company fell 1% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PPS","BK7503","BK7016","PAR.AU","PPS.AU","BK7067"],"gpt_icon":0},{"id":"2610350119","title":"BRIEF-Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2610350119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610350119?lang=en_us&edition=fundamental","pubTime":"2026-02-09 09:42","pubTimestamp":1770601357,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Signs Binding Veterinary Licensing & Supply AgreementFeb 9  - Paradigm Biopharmaceuticals Ltd PAR.AX:SIGNS BINDING VETERINARY LICENSING & SUPPLY AGREEMENT FOR ORAL PPS + COX-2 INHIBITOR COMBINATIONCO ELIGIBLE TO RECEIVE UP TO A$1 MILLION FROM AVET IN DEVELOPMENT MILESTONESFurther company coverage: PAR.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nFWN3Z21W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2610506213","title":"Paradigm Biopharmaceuticals Secures Binding Term Sheet With Veterinary Pharmaceutical Company; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610506213","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610506213?lang=en_us&edition=fundamental","pubTime":"2026-02-09 08:42","pubTimestamp":1770597732,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  secured a binding term sheet with AVet Health for the co-development and licensing of an oral combination therapy for the treatment of osteoarthritis in companion animals, according to a Monday filing with the Australian bourse.AVet Health will hold exclusive rights in Australia and New Zealand under the deal, with a first right of refusal for all other markets excluding the US, with the company eligible to receive up to AU$1 million in development milestones, the filing said.Once the licensing agreement is finalized, the company will receive tiered royalties of up to 20% on net sales and run for 15 years post-registration with the Australian Pesticides and Veterinary Medicines Authority, per the filing.Paradigm Biopharmaceuticals shares rose 3% in morning trade on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","PAR.AU"],"gpt_icon":0},{"id":"2610508204","title":"Paradigm Biopharmaceuticals Ltd - Signs Binding Veterinary Licensing & Supply Agreement for Oral PPS + Cox-2 Inhibitor Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2610508204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610508204?lang=en_us&edition=fundamental","pubTime":"2026-02-09 06:08","pubTimestamp":1770588502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nFWN3Z21W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2610150820","title":"Paradigm Biopharmaceuticals -Co Eligible to Receive up to a$1 Mln From Avet in Development Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2610150820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610150820?lang=en_us&edition=fundamental","pubTime":"2026-02-09 06:08","pubTimestamp":1770588502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nFWN3Z21W1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2608386928","title":"Paradigm Biopharmaceuticals Ltd-Change of Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2608386928","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608386928?lang=en_us&edition=fundamental","pubTime":"2026-02-04 06:30","pubTimestamp":1770157803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUE4FC0YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2603152640","title":"Papa John's International Collaborates With PAR Technology to Modernize Restaurant Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2603152640","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603152640?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:23","pubTimestamp":1768253027,"startTime":"0","endTime":"0","summary":"Papa John's International  said late Monday it entered a collaboration with PAR Technology  to leverage PAR POS and PAR OPS to modernize its in-restaurant technology stack as part of efforts to create a more intelligent restaurant and digital ordering experience.The company will utilize PAR's enterprise offerings to bring front-of-house ordering, make-line operations, above-restaurant management, and AI-driven labor and inventory management, according to a statement.Real-time data shared through a unified platform will enhance visibility into operational metrics and enable teams to operate with greater discipline, the company said.Financial details of the deal were not disclosed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2065731478.USD","PZZA","BK7508","PAR","BK4209","QSR","BK7067","LU0353189763.USD","PAR.AU","BK4157","LU2087625088.SGD","LU0353189680.USD","BK4023"],"gpt_icon":0},{"id":"2593456501","title":"Paradigm Biopharmaceuticals Moves to Reach Patient Recruitment Milestone in Phase 3 Knee Osteoarthritis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593456501","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593456501?lang=en_us&edition=fundamental","pubTime":"2025-12-23 07:10","pubTimestamp":1766445036,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said it has the required number of participants to meet the 25% recruitment milestone for its phase 3 PARA_OA_012 clinical trial, according to a Tuesday filing with the Australian bourse.The trial is evaluating the company's drug candidate, injectable pentosan polysulfate sodium, for the potential treatment of knee osteoarthritis, the filing said.The company expects to start dosing a number of participants in the trial next year, and sees the 50% recruitment milestone achieved shortly after the completion of the 25% dosing milestone, the filing added.The company said it is on track for an interim analysis of the trial in mid-2026. The primary endpoint analysis for the full patient group is expected in the fourth quarter of 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2592194851","title":"PAR Technology (PAR) Valuation After Wasatch Exit and Ongoing Cash Burn Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2592194851","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592194851?lang=en_us&edition=fundamental","pubTime":"2025-12-20 01:16","pubTimestamp":1766164597,"startTime":"0","endTime":"0","summary":"PAR Technology (PAR) is back in the spotlight after Wasatch Global Investors exited its position, citing weaker than expected organic growth, just as the company leans on new products like Smart Passes to reset its story.\nSee our latest analysis for PAR Technology.\nThat backdrop helps explain why, even with a recent 1 month share price return of about 8 percent and a 1 day gain of nearly 3 percent to 36.83 dollars, PAR’s year to date share price return is still deep in the red. Its 1 year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/par-technology-par-valuation-after-wasatch-exit-and-ongoing","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/par-technology-par-valuation-after-wasatch-exit-and-ongoing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","BK4157","PAR","PAR.AU","BK4023"],"gpt_icon":0},{"id":"2591644312","title":"PAR Technology (PAR) Taps Wallet-Based Loyalty But How Durable Is Its Restaurant Software Edge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644312","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644312?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:11","pubTimestamp":1765797107,"startTime":"0","endTime":"0","summary":"In early December 2025, PAR Technology launched Smart Passes, a wallet-native loyalty solution within its Punchh platform that uses Apple and Google Wallet for real-time, app-free rewards, and Abelardo's Mexican Fresh selected PAR's unified POS, payments, engagement, and operations tools to upgrade its restaurant technology stack.\nTogether, these moves highlight how PAR is deepening its presence in restaurant loyalty and winning full-suite deployments that can increase customer stickiness...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/par-technology-par-taps-wallet-based-loyalty-but-how-durable","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/par-technology-par-taps-wallet-based-loyalty-but-how-durable","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PAR","BK7508","PAR.AU","BK7067","BK4209","QSR","BK4023","BK4157"],"gpt_icon":0},{"id":"2584661528","title":"Paradigm Biopharmaceuticals Withdraws About $5 Million From Convertible Note Facility; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584661528","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584661528?lang=en_us&edition=fundamental","pubTime":"2025-11-17 12:05","pubTimestamp":1763352307,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  has withdrawn about $5 million from its $27 million Convertible Note Facility with Obsidian Global Partners, according to a Monday filing with the Australian bourse.Funds will be used as additional working capital for the company's phase three clinical trial, the filing said.The remaining $15 million in the facility will be used to support ongoing phase three activities, regulatory engagement, and commercial-readiness programs, the filing added.Shares of the company rose 7% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2582374086","title":"PAR Technology Launches Catering Platform to Help Chains Manage Large Orders","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374086","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374086?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:54","pubTimestamp":1762955652,"startTime":"0","endTime":"0","summary":"PAR Technology  said Wednesday it launched PAR Catering to help restaurants run large-order catering alongside daily operations with integration to its existing Ordering suite.The product includes a centralized order desk that manages orders across stores, call centers, and online channels, while keeping kitchens on schedule, the company said.Headcount-based recommendations and per-person pricing simplify ordering, while CRM and account tools support loyalty and one-click reorders, the company added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4157","PAR","PAR.AU","BK4023","BK7508"],"gpt_icon":0},{"id":"2582387346","title":"Paradigm Biopharmaceuticals Engages Complementary Contract Research Organization to Support Knee Osteoarthritis Trial; Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582387346","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582387346?lang=en_us&edition=fundamental","pubTime":"2025-11-12 13:02","pubTimestamp":1762923737,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  engaged Nordic Bioscience Clinical Development as a complementary contract research organization to support the firm's ongoing pivotal third phase PARA_OA_012 clinical trial in knee osteoarthritis, according to a Wednesday Australian bourse filing.Nordic Bioscience will work collaboratively with Paradigm and Advanced Clinical, its global lead contract research organization, to activate and manage four additional clinical sites, one in Hong Kong and three in Moldova. These sites are expected to be activated in December and start recruitment in January 2026.A clinical presence in Hong Kong will allow new drugs approved by a single recognized reference authority to apply for registration in Hong Kong under the recently introduced \"1+\" regulatory mechanism, provided supporting local clinical data and expert recognition are submitted.Paradigm expects to finalize the activation of sites at around 60 globally.The company's shares fell 5% in recent trading on Wedne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2582848157","title":"PAR Technology (PAR) Is Up 9.4% After AI Platform Launch and 23% Revenue Growth in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2582848157","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582848157?lang=en_us&edition=fundamental","pubTime":"2025-11-10 09:23","pubTimestamp":1762737809,"startTime":"0","endTime":"0","summary":"PAR Technology Corporation recently reported third-quarter 2025 results, highlighting a 23% year-over-year increase in revenue to US$119.18 million and strong growth in annual recurring revenue, driven by its software subscription business and hardware sales.\nThe company emphasized the successful launch of its AI-enabled platform tools, such as Coach AI, which are designed to boost operational efficiency for restaurant operators and have accelerated multiproduct adoption across its client...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/par-technology-par-is-up-94-after-ai-platform-launch-and-23","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/par-technology-par-is-up-94-after-ai-platform-launch-and-23","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PAR.AU","PAR"],"gpt_icon":0},{"id":"2579198636","title":"Paradigm Biopharmaceuticals Enters Phase Three Trial Dosing Phase for Knee Osteoarthritis Pain in the September Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2579198636","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579198636?lang=en_us&edition=fundamental","pubTime":"2025-10-30 14:41","pubTimestamp":1761806505,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said it entered the dosing phase of its global phase three clinical trial evaluating injectable pentosan polysulfate sodium for pain associated with knee osteoarthritis, with participants randomized and dosed in both Australia and the US, according to a Thursday Australian bourse filing.The total target enrollment remains 466 participants, with the interim analysis planned once 50% of participants reach day 112, which is anticipated to occur in mid-2026.All selected trial sites across Australia and the US are expected to be active and recruiting by early November. It continues to evaluate the potential inclusion of additional sites outside these two countries to further support recruitment.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","XKO.AU","BK7067","XJO.AU","XAO.AU"],"gpt_icon":0},{"id":"2577510460","title":"Can Paradigm Biopharmaceuticals' (ASX:PAR) Leadership Vision Drive Long-Term Strategic Value?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577510460","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577510460?lang=en_us&edition=fundamental","pubTime":"2025-10-24 22:31","pubTimestamp":1761316298,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals Limited presented at the Ignite Investment Summit in Hong Kong on October 15, 2025, with Founder, MD & Executive Chairman Paul John Rennie delivering key insights.\nThe company's participation at this high-profile investor event provided stakeholders with detailed updates on its strategic direction and executive leadership vision.\nWe'll explore how Paradigm Biopharmaceuticals' focus on its executive leadership vision at the summit shapes its current investment...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/can-paradigm-biopharmaceuticals-asxpar-leadership-vision-dri","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/can-paradigm-biopharmaceuticals-asxpar-leadership-vision-dri","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PAR.AU","BK4157","BK4023","BK7508","BK7067","PAR"],"gpt_icon":0},{"id":"2577610588","title":"Paradigm Biopharmaceuticals (ASX:PAR): Assessing Valuation as Investor Focus Builds Ahead of Ignite Summit Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2577610588","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577610588?lang=en_us&edition=fundamental","pubTime":"2025-10-23 18:32","pubTimestamp":1761215575,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals (ASX:PAR) is drawing increased attention ahead of its scheduled presentation at the Ignite Investment Summit in Hong Kong, where the company’s founder and executive team will address investors.\nSee our latest analysis for Paradigm Biopharmaceuticals.\nAfter a year defined by volatility, Paradigm's share price has rebounded sharply with a 56% gain over the past month. This signals fresh momentum ahead of its summit appearance. While the short-term rally is grabbing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-asxpar-assessing-valuation-as-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-asxpar-assessing-valuation-as-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PAR.AU","BK4157","BK4023","BK7508","SMMF","BK7067","BK4211","PAR"],"gpt_icon":0},{"id":"2574460483","title":"Paradigm Biopharmaceuticals (ASX:PAR) Raises Capital—Will New Funds Accelerate Its Therapeutic Pipeline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2574460483","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574460483?lang=en_us&edition=fundamental","pubTime":"2025-10-11 01:31","pubTimestamp":1760117508,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals recently announced the quotation of over 11 million new ordinary fully paid securities on the Australian Securities Exchange to enhance its financial flexibility.\nThis move aims to support the progress of therapies targeting inflammatory diseases, strengthening the company's position in musculoskeletal disorder treatment development.\nWe'll explore how raising capital for ongoing development projects shapes Paradigm Biopharmaceuticals’ investment narrative and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-asxpar-raises-capitalwill-new-fu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-asxpar-raises-capitalwill-new-fu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","AAQC","PAR","PAR.AU","BK4157","BK4023","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}